InvestorsHub Logo
Followers 20
Posts 456
Boards Moderated 0
Alias Born 10/27/2012

Re: None

Wednesday, 05/13/2015 2:01:35 PM

Wednesday, May 13, 2015 2:01:35 PM

Post# of 3833
It may be that La Jolla Pharmaceutical (NASDAQ:LJPC) is to be applauded for cutting its losses and ditching its two kidney disease candidates GCS-100 and LJPC-1010 after the FDA insisted on the kind of chemical composition data that would have been hard and expensive to acquire. Shareholders, though, were disappointed, sending its shares down 15% to $16.49 on Friday.

LJPC 1010 was gelactine 3 inhibitor from oranges. Ours - Apples.

It is highly likely the FDA will ask us the same thing.

Any idea about the cost or what are the ricks we can get similar request?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News